Apexigen, a biopharmaceutical company, went public via a SPAC merger with Brookline Capital Acquisition, a blank cheque company, in a $205m deal. “We are thrilled to partner with Apexigen to power the next generation of immuno-oncology therapeutics. Apexigen’s validated APXiMAB antibody discovery platform and expanding pipeline hold significant promise across multiple cancer indications with high unmet needs, as well as potential applications beyond oncology. We have great confidence in management’s ability to lead Apexigen through this next phase of growth as a publicly listed company, to reach new inflection points across its pipeline and to drive long-term value for stockholders," Samuel P. Wertheimer, Brookline Capital Chairman and CEO.